(Q40335438)

19 September 2017

title

PCV13 serotype decrease in Italian adolescents and adults in the post-PCV13 era: Herd protection from children or secular trend? (English)

1 reference

19 September 2017

10

1 reference

19 September 2017

2

0 references

Maria Paola Landini

8

object named as

Maria Paola Landini

1 reference

19 September 2017

9

Assunta Sartor

1 reference

19 September 2017

Francesco Nieddu

1

1 reference

19 September 2017

Elisa De Vitis

3

1 reference

19 September 2017

Silvia Ricci

4

1 reference

19 September 2017

Giuseppe Indolfi

5

1 reference

19 September 2017

Massimo Resti

6

1 reference

19 September 2017

Caterina Vocale

7

1 reference

19 September 2017

Italian group for the study of Invasive Pneumococcal Disease

11

1 reference

19 September 2017

language of work or name

English

0 references

publication date

9 February 2017

1 reference

19 September 2017

1 reference

19 September 2017

volume

35

1 reference

19 September 2017

issue

11

1 reference

19 September 2017

page(s)

1544-1550

1 reference

Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Secular trends (1990-2013) in serotypes and associated non-susceptibility of S. pneumoniae isolates causing invasive disease in the pre-/post-era of pneumococcal conjugate vaccines in Spanish regions without universal paediatric pneumococcal vaccina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Decreases in case-fatality and mortality rates for invasive pneumococcal disease in Olmsted County, Minnesota, during 1995-2007: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Epidemiology of Invasive Pneumococcal Disease among Adult Patients in Barcelona Before and After Pediatric 7‐Valent Pneumococcal Conjugate Vaccine Introduction, 1997–2007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Inferring the potential success of pneumococcal vaccination in Italy: serotypes and antibiotic resistance of Streptococcus pneumoniae isolates from invasive diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Community‐acquired bacteremic pneumococcal pneumonia in children: diagnosis and serotyping by real‐time polymerase chain reaction using blood samples.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Detection and serotyping of lyophilized nonculturable pneumococcal isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Realtime PCR is more sensitive than multiplex PCR for diagnosis and serotyping in children with culture negative pneumococcal invasive disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Potential serotype coverage of three pneumococcal conjugate vaccines against invasive pneumococcal infection in Italian children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Serotype Changes and Drug Resistance in Invasive Pneumococcal Diseases in Adults after Vaccinations in Children, Japan, 2010-2013.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001–2013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

The potential indirect effect of conjugate pneumococcal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Pneumococcal serotype distribution in 1315 nasopharyngeal swabs from a highly vaccinated cohort of Italian children as detected by RT-PCR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Serotypes and Clonal Diversity of Streptococcus pneumoniae Causing Invasive Disease in the Era of PCV13 in Catalonia, Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Application of capsular sequence typing (CST) to serotype non-viable Streptococcus pneumoniae isolates from an old collection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Pneumococcal serotype evolution in Western Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Impact of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae among children attending group daycare in southeastern France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.064

10.1016/J.VACCINE.2017.01.064

7 January 2021

Identifiers

DOI

1 reference

19 September 2017

1 reference